Loss of Siglec expression on T lymphocytes during human evolution
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
We report here that human T cells give much stronger proliferative responses to specific activation via the T cell receptor (TCR) than those from chimpanzees, our closest evolutionary relatives. Nonspecific activation using phytohemagglutinin was robust in chimpanzee T cells, indicating that the much lower response to TCR simulation is not due to any intrinsic inability to respond to an activating stimulus. CD33-related Siglecs are inhibitory signaling molecules expressed on most immune cells and are thought to down-regulate cellular activation pathways via cytosolic immunoreceptor tyrosine-based inhibitory motifs. Among human immune cells, T lymphocytes are a striking exception, expressing little to none of these molecules. In stark contrast, we find that T lymphocytes from chimpanzees as well as the other closely related “great apes” (bonobos, gorillas, and orangutans) express several CD33-related Siglecs on their surfaces. Thus, human-specific loss of T cell Siglec expression occurred after our last common ancestor with great apes, potentially resulting in an evolutionary difference with regard to inhibitory signaling. We confirmed this by studying Siglec-5, which is prominently expressed on chimpanzee lymphocytes, including CD4 T cells. Ab-mediated clearance of Siglec-5 from chimpanzee T cells enhanced TCR-mediated activation. Conversely, primary human T cells and Jurkat cells transfected with Siglec-5 become less responsive; i.e., they behave more like chimpanzee T cells. This human-specific loss of T cell Siglec expression associated with T cell hyperactivity may help explain the strikingly disparate prevalence and severity of T cell-mediated diseases such as AIDS and chronic active hepatitis between humans and chimpanzees.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, a recent study showed that chimpanzee T cells are also less responsive towards in vitro stimulation than human T cells and it was suggested that this might be due to loss of Siglec expression on human T cells [45].”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [45]
In the citing paper
“Siglecs are inhibitory receptors that are related to CD33 and it appears as if their expression is lost on T cells during evolution from monkey to human [45].”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [45]
In the citing paper
“human T cells express little to none of the CD33-related siglecs, which are inhibitory signaling molecules on the cell surface that downregulate cellular activation pathways (12).”
From The calm after the cytokine storm: lessons from the TGN1412 trial (2008) · cites this paper as [12]
In the citing paper
“In contrast, chimpanzees and monkeys express abundant levels of CD33-related siglecs on the surface of their T cells, which also show lower amounts of T cell proliferation and activation than their human counterparts upon stimulation with anti-CD3 and antiCD28 antibodies.”
From The calm after the cytokine storm: lessons from the TGN1412 trial (2008) · cites this paper as [12]
Citations
Cites
Initial sequence of the chimpanzee genome and comparison with the human genome
The Chimpanzee Sequencing and Analysis Consortium (2005) · Nature · doi:10.1038/nature04072 · Cited by 2,459
Ravetch, J. V., & Lanier, L. L. (2000) · Science · doi:10.1126/science.290.5489.84 · Cited by 1,283
Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif
Mariani, R., Chen, D., Schröfelbauer, B., Navarro, F., König, R., Bollman, B., Münk, C., Nymark-McMahon, H., & Landau, N. R. (2003) · Cell · doi:10.1016/s0092-8674(03)00515-4 · Cited by 903
Wood, B., & Collard, M. (1999) · Science · doi:10.1126/science.284.5411.65 · Cited by 714
Siglecs—the major subfamily of I-type lectins
Varki, A., & Angata, T. (2006) · Glycobiology · doi:10.1093/glycob/cwj008 · Cited by 518
Self-citationSiglecs, sialic acids and innate immunity
Crocker, P. R., & Varki, A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01930-5 · Cited by 382
Self-citationMitochondrial sequences show diverse evolutionary histories of African hominoids
Gagneux, P., Wills, C., Gerloff, U., Tautz, D., Morin, P. A., Boesch, C., Fruth, B., Hohmann, G., Ryder, O. A., & Woodruff, D. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5077 · Cited by 350
Self-citationComparing the human and chimpanzee genomes: Searching for needles in a haystack
Varki, A., & Altheide, T. K. (2005) · Genome Research · doi:10.1101/gr.3737405 · Cited by 344
Self-citationVarki, A. (2001) · American Journal of Physical Anthropology · doi:10.1002/ajpa.10018 · Cited by 324
Self-citationTransmission of HTLV-III Infection from Human Plasma to Chimpanzees: An Animal Model for AIDS
Alter, H. J., Eichberg, J. W., Masur, H., Saxinger, W. C., Gallo, R., Macher, A. M., Lane, H. C., & Fauci, A. S. (1984) · Science · doi:10.1126/science.6093251 · Cited by 319
Research works printed but not linked: 1
- P. Gagneux, E. A. Muchmore Methods Mol. Med 96, 289–318 (2004).
Cited by
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031
Self-citationThe safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“81 83-88 However, if the observed toxicity was indeed related to the catabolism of the capsid, then this aspect of drug metabolism needed to be understood in greater detail.”
Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins
Varki, A. (2007) · Nature · doi:10.1038/nature05816 · Cited by 853
Self-citationPD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
“Siglec expression limits chimpanzee T-cell expansion and is thought to contribute to the differential severity of T-cell-mediated diseases, such as acquired immunodeficiency syndrome and chronic active hepatitis, between humans and chimpanzees (35).”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Smith, B. A. H., & Bertozzi, C. R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00093-1 · Cited by 500
Diversity in cell surface sialic acid presentations: implications for biology and disease
Varki, N. M., & Varki, A. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700656 · Cited by 515
“For example, the human-specific evolutionary loss of immune-regulating Siglec molecules on T cells may account for the hyperactivity of human T cells, and our apparent propensity to develop diseases mediated related T cell dysfunction.(24) On the other hand, we have suggested that recent evolutionary changes in the bi…”
BackgroundSelf-citationSialic acids in cancer biology and immunity
Pearce, O. M. T., & Läubli, H. (2016) · Glycobiology · doi:10.1093/glycob/cwv097 · Cited by 470
Finch, C. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909606106 · Cited by 407
“Differences in the Siglec lectin family of proteins (Ig superfamily) cell-surface glycoproteins have specific implications for host-defense evolution in studies from Varki and coworkers (92, 93).”
BackgroundInfluentialPadler-Karavani, V., Yu, H., Cao, H., Chokhawala, H., Karp, F., Varki, N., Chen, X., & Varki, A. (2008) · Glycobiology · doi:10.1093/glycob/cwn072 · Cited by 326
“…were diluted 1:3 in the blocking solution containing 10% chimpanzee plasma (a rich source of Neu5Gc-containing glycoproteins; obtained as described (Nguyen et al. 2006)), incubated for 2 h at 4◦C, then applied over tissue sections and incubated at RT for 1 h. Subsequently, tissues were…”
MethodSelf-citationStebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Stanczak, M. A., Siddiqui, S. S., Trefny, M. P., Thommen, D. S., Boligan, K. F., von Gunten, S., Tzankov, A., Tietze, L., Lardinois, D., Heinzelmann-Schwarz, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120612 · Cited by 296
“We and others have shown that T cells from healthy humans express low levels of CD33related Siglecs (29, 35).”
Self-citationParedes Juárez, G. A., Spasojevic, M., Faas, M. M., & de Vos, P. (2014) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2014.00026 · Cited by 284
“Human CD4 T cells have low expression of Siglecs relative to chimpanzees (Nguyen et al., 2006).”
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
“…suggested that differences in human- and macaque TGN1412-driven responses are due to the expression of inhibitory Siglecs on non-human primate T-cells, which have been lost during human evolution, rendering them less responsive to in vitro stimulation (Nguyen et al., 2006; Waibler et al., 2008).”
BackgroundThe influence of evolutionary history on human health and disease
Benton, M. L., Abraham, A., LaBella, A. L., Abbot, P., Rokas, A., & Capra, J. A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00305-9 · Cited by 291
Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis
Läubli, H., & Borsig, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02120 · Cited by 282
“Inhibition of the sialoglycan-Siglec axis with blocking antibodies or genetic models enhances T cell-mediated anti-cancer immunity in vitro and in vivo (51, 66, 67).”
BackgroundUniquely human evolution of sialic acid genetics and biology
Varki, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914634107 · Cited by 278
“Regardless of the reason, we found that human T cells reacted more strongly to stimulation (67, 68).”
BackgroundSelf-citationSafety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J. (2010) · mAbs · doi:10.4161/mabs.2.3.11782 · Cited by 250
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Läubli, H., Pearce, O. M. T., Schwarz, F., Siddiqui, S. S., Deng, L., Stanczak, M. A., Deng, L., Verhagen, A., Secrest, P., Lusk, C., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409580111 · Cited by 228
“Moreover, Siglec-9 is also expressed on a subgroup of CD8 T cells (45), although at a low level (46).”
BackgroundSelf-citationMultiple changes in sialic acid biology during human evolution
Varki, A. (2009) · Glycoconjugate Journal · doi:10.1007/s10719-008-9183-z · Cited by 219
“Regardless, there does appear to be a functional consequence, that human T cells were found to be more reactive than chimpanzee T cells when stimulated through the T cell receptor complex [92].”
BackgroundInfluentialSelf-citationSialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment
van de Wall, S., Santegoets, K. C. M., van Houtum, E. J. H., Büll, C., & Adema, G. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.02.001 · Cited by 208
Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils
Zhang, M., Angata, T., Cho, J. Y., Miller, M., Broide, D. H., & Varki, A. (2007) · Blood · doi:10.1182/blood-2006-08-039255 · Cited by 204
Self-citationTreatment of allergic asthma: Modulation of Th2 cells and their responses
Bosnjak, B., Stelzmueller, B., Erb, K. J., & Epstein, M. M. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-114 · Cited by 204
Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Läubli, H., & Varki, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03288-x · Cited by 204
Self-citationT cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10
Bandala-Sanchez, E., Zhang, Y., Reinwald, S., Dromey, J. A., Lee, B.-H., Qian, J., Böhmer, R. M., & Harrison, L. C. (2013) · Nature Immunology · doi:10.1038/ni.2610 · Cited by 198
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192
“Human T cells also proliferate more vigorously after TCR activation than do T cells from chimpanzees, and this difference has been attributed to loss of inhibitory Siglec expression during human evolution (46).”
BackgroundSiglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions
Kiwamoto, T., Kawasaki, N., Paulson, J. C., & Bochner, B. S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.06.005 · Cited by 183
“Because human CD4+ lymphocytes have evolved to lack them (Nguyen et al., 2006), siglecs are often thought of as innate immune receptors (Crocker, 2005), although CD8+ T cells can express Siglec-7 and Siglec-9 (Ikehara et al., 2004), and under allergic inflammatory conditions, Siglec-F can…”
BackgroundImmunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Challenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 185
“Despite the similarities between the immune systems of humans and non-human primates (NHPs), there are substantial functional inter-species differences in T cell activation, which have important consequences for safety assessments and the prediction of cytokine release syndrome (CRS) 125 .”
BackgroundAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Human uniqueness: genome interactions with environment, behaviour and culture
Varki, A., Geschwind, D. H., & Eichler, E. E. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2428 · Cited by 167
“One candidate for explaining this difference is suppression of expression of inhibitory SIGLEC genes in human T cell”
BackgroundSelf-citationEvolution of genetic and genomic features unique to the human lineage
O'Bleness, M., Searles, V. B., Varki, A., Gagneux, P., & Sikela, J. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3336 · Cited by 168
Self-citationBasic and Clinical Immunology of Siglecs
Von Gunten, S., & Bochner, B. S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.011 · Cited by 167
Monoclonal antibody-induced cytokine-release syndrome
Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G., & Bouman-Thio, E. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.31 · Cited by 161
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
“This may be explained by several phenotypic differences between capsid-specific CTLs in humans and nonhuman primates.(9,31) Our new study sought to establish a suitable murine model for preclinical testing of the effect of capsid-specific CD8(1) T cells on therapeutic hepatocyte-derived F.”
BackgroundSweet escape: Sialic acids in tumor immune evasion
Büll, C., den Brok, M. H., & Adema, G. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.005 · Cited by 158
The extended human leukocyte receptor complex: diverse ways of modulating immune responses
Barrow, A. D., & Trowsdale, J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00653.x · Cited by 165
Adeno-Associated Virus Gene Therapy for Liver Disease
Kattenhorn, L. M., Tipper, C. H., Stoica, L., Geraghty, D. S., Wright, T. L., Clark, K. R., & Wadsworth, S. C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.160 · Cited by 138
“However, speculation suggests it may be due to the loss of a subset of inhibitory immunoglobulin-like lectins on human T cells during evolution.(92) Further proof of this remains to be demonstrated, however.”
BackgroundSiglec receptors as new immune checkpoints in cancer
Stanczak, M. A., & Laubli, H. P. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101112 · Cited by 143
Role of Nef in primate lentiviral immunopathogenesis
Kirchhoff, F., Schindler, M., Specht, A., Arhel, N. J., & Münch, J. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8094-2 · Cited by 128
Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium
Pham, T., Gregg, C. J., Karp, F., Chow, R., Padler-Karavani, V., Cao, H., Chen, X., Witztum, J. L., Varki, N. M., & Varki, A. (2009) · Blood · doi:10.1182/blood-2009-05-220400 · Cited by 123
Self-citationThe domestic dog: man's best friend in the genomic era
Boyko, A. R. (2011) · Genome Biology · doi:10.1186/gb-2011-12-2-216 · Cited by 123
“Some human adaptations to this dramatic environmental shift that contribute through antago nistic pleiotropy to disease (such as highly reactive immune systems that protect from infectious disease but predispose individuals to autoimmune disorders [49,50]) might have evolved in parallel in dogs.”
BackgroundHuman-specific expression of Siglec-6 in the placenta
Brinkman-Van der Linden, E. C. M., Hurtado-Ziola, N., Hayakawa, T., Wiggleton, L., Benirschke, K., Varki, A., & Varki, N. (2007) · Glycobiology · doi:10.1093/glycob/cwm065 · Cited by 123
“Other examples of human-specific changes in CD33rSiglec expression include T lymphocytes (Nguyen et al., 2006) and brain microglia (Hayakawa et al.”
BackgroundSelf-citationLinnartz, B., & Neumann, H. (2013) · Glia · doi:10.1002/glia.22359 · Cited by 116
“, 2010), the induction of cell death (Nguyen et al., 2006) and endocytosis (Lock et al.”
BackgroundPreclinical safety testing of monoclonal antibodies: the significance of species relevance
Chapman, K., Pullen, N., Graham, M., & Ragan, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2242 · Cited by 121
“For example, some of the effects of TGN1412 might have also been masked in the chimpanzee owing to the human-specific loss of expression of CD33-related Siglecs, which are inhibitors of T-cell cellular activation, resulting in an evolutionary difference between humans and chimpanzees with regard to inhibitory signalli…”
BackgroundMünch, J., Rajan, D., Schindler, M., Specht, A., Rücker, E., Novembre, F. J., Nerrienet, E., Müller-Trutwin, M. C., Peeters, M., Hahn, B. H., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00904-07 · Cited by 120
“For instance, a recent study suggests that chimpanzees are less susceptible to disease because their T cells express high levels of sialic acid-binding immunoglobulin-like lectins and are, therefore, less responsive to activation (13, 50).”
BackgroundVarki, N. M., Strobert, E., Dick, E. J., Benirschke, K., & Varki, A. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130315 · Cited by 114
“First, we found that human lymphocytes are more reactive than those of chimpanzees (57, 58), which may represent a potential mechanism for accelerating the inflammation observed in human atherosclerotic lesions.”
BackgroundSelf-citationKehrer‐Sawatzki, H., & Cooper, D. N. (2006) · Human Mutation · doi:10.1002/humu.20420 · Cited by 122
“Further, the human-specific loss of Siglec expression on T cells is associated with Tcell hyperactivity, which might itself be related to the striking differences between humans and chimpanzees in terms of both the prevalence and severity of T-cell mediated diseases, such as acquired immunodeficiency syndrome (AIDS) […”
BackgroundInfluentialVarki, N., Anderson, D., Herndon, J. G., Pham, T., Gregg, C. J., Cheriyan, M., Murphy, J., Strobert, E., Fritz, J., Else, J. G., et al. (2009) · Evolutionary Applications · doi:10.1111/j.1752-4571.2008.00064.x · Cited by 109
“Another contributing factor could be the hyper-reactive phenotype of human T cells, relative to those of chimpanzees (Nguyen et al. 2006; Varki 2008), potentially aggravating the chronic inflammation seen in atherosclerotic plaques.”
Self-citationMuller, P., & Brennan, F. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.273 · Cited by 104
Deletion polymorphism of SIGLEC14 and its functional implications
Yamanaka, M., Kato, Y., Angata, T., & Narimatsu, H. (2009) · Glycobiology · doi:10.1093/glycob/cwp052 · Cited by 107
Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200090 · Cited by 102
“domain of CD28, the loss of Siglec-5 expression during human evolution (11, 12), or a different expression pattern of CD28 on a specific T cell subset (13).”
BackgroundPreclinical development of monoclonal antibodies: Considerations for the use of non-human primates
Chapman, K. L., Pullen, N., Coney, L., Dempster, M., Andrews, L., Bajramovic, J. J., Baldrick, P., Buckley, L. A., Jacobs, A., Hale, G., et al. (2009) · mAbs · doi:10.4161/mabs.1.5.9676 · Cited by 109
“Although the human and NHP immune systems have many similarities there are some significant functional differences, particularly with regard to T-cell activation which differs even between human and chimpanzee.(18,19)”
BackgroundMurphy, S. L., & High, K. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06942.x · Cited by 112
“There is some evidence that T cells in humans may be more sensitive than T cells in non-human primates as a result of differential expression of an immunomodulatory lectin (Nguyen et al, 2006).”
BackgroundMiyazaki, K., Sakuma, K., Kawamura, Y. I., Izawa, M., Ohmori, K., Mitsuki, M., Yamaji, T., Hashimoto, Y., Suzuki, A., Saito, Y., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100605 · Cited by 91
“Human peripheral blood T cells had been known to contain a very small number, if any, of siglec-7/-9 cells, and the significance of such siglec-7/-9 CD8 T cells has largely been overlooked (32).”
BackgroundBärenwaldt, A., & Läubli, H. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1667977 · Cited by 92
“cussed earlier, human T cells have a low expression of inhibitory Siglec receptors [49,132].”
BackgroundSialic acids and autoimmune disease
Mahajan, V. S., & Pillai, S. (2016) · Immunological Reviews · doi:10.1111/imr.12344 · Cited by 88
Targeting Siglecs—A novel pharmacological strategy for immuno- and glycotherapy
Jandus, C., Simon, H., & von Gunten, S. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.018 · Cited by 103
Horvath, C. J., & Milton, M. N. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332986 · Cited by 87
“Other mechanisms may explain differences in T cell activation and cytokine release, such as differential expression of immune regulatory molecules (e.g., Siglecs) between humans and nonhuman primates, including chimpanzees (Nguyen et al. 2006).”
BackgroundOkerblom, J., & Varki, A. (2017) · ChemBioChem · doi:10.1002/cbic.201700077 · Cited by 79
Self-citationDiscovery, classification, evolution and diversity of Siglecs
Angata, T., & Varki, A. P. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101117 · Cited by 86
Self-citationPoirier, N., Mary, C., Dilek, N., Hervouet, J., Minault, D., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04164.x · Cited by 83
“This immunological toxicity could be explained by a relative loss of expression of inhibitory sialic acid-recognizing Ig-superfamily lectins (Siglec, CD33) on lymphocytes during human evolution (55,56).”
BackgroundPadler‐Karavani, V., Hurtado‐Ziola, N., Chang, Y., Sonnenburg, J. L., Ronagh, A., Yu, H., Verhagen, A., Nizet, V., Chen, X., Varki, N., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-241497 · Cited by 79
“We had previously shown that humans express very low levels of CD33rSiglecs on their lymphocytes in contrast with those for other great apes (46).”
ResultSelf-citationSignaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001708 · Cited by 79
“Importantly, a recent study showed that chimpanzee T cells are also less responsive towards in vitro stimulation than human T cells and it was suggested that this might be due to loss of Siglec expression on human T cells [45].”
BackgroundThe calm after the cytokine storm: lessons from the TGN1412 trial
St. Clair, E. W. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35382 · Cited by 79
Dynamic evolution of regulatory element ensembles in primate CD4+ T cells
Danko, C. G., Choate, L. A., Marks, B. A., Rice, E. J., Wang, Z., Chu, T., Martins, A. L., Dukler, N., Coonrod, S. A., Tait Wojno, E. D., et al. (2018) · Nature Ecology & Evolution · doi:10.1038/s41559-017-0447-5 · Cited by 72
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Röhrig, C. H., Choi, S. S. H., & Baldwin, N. J. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1040113 · Cited by 79
“may explain to some extent the adverse and unanticipated immunological reactions that have arisen during a number of human clinical trials on biotherapeutic antibodies (Nguyen et al., 2006; Wadman, 2006).”
BackgroundInfluentialSafety of biologics, lessons learnt from TGN1412
Stebbings, R., Poole, S., & Thorpe, R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.002 · Cited by 70
Siglec‐5 is an inhibitory immune checkpoint molecule for human T cells
Vuchkovska, A., Glanville, D. G., Scurti, G. M., White, P., Nishimura, M. I., Ulijasz, A. T., & Iwashima, M. (2022) · Immunology · doi:10.1111/imm.13470 · Cited by 73
“In contrast, little to no expression is reported in T cells (15), with the exception of Siglec-7 and -9, which are expressed by small populations of CD8+ T cells and mediate direct inhibition of TCR signaling (16).”
BackgroundDiversity and evolution of the primate skin microbiome
Sarah Council, Savage, A. M., Urban, J., Ehlers, M. E., Skene, J. H. P., Platt, M. L., Dunn, R. R., & Horvath, J. E. (2016) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2015.2586 · Cited by 71
Functions and therapeutic targets of Siglec-mediated infections, inflammations and cancers
Lin, C.-H., Yeh, Y.-C., & Yang, K. D. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.10.019 · Cited by 57
Siglecs as Therapeutic Targets in Cancer
Lim, J., Sari-Ak, D., & Bagga, T. (2021) · Biology · doi:10.3390/biology10111178 · Cited by 50
“More interestingly, resting T cells normally express few or no Siglecs, but Siglec-5 is found expressed on activated tumor infiltrating T lymphocytes of various cancers, which can lead to T cell exhaustion [13,71,72].”
BackgroundCauvin, A. J., Peters, C., & Brennan, F. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417144-2.00019-6 · Cited by 77
“By contrast, marmosets exhibit limited diversity at MHC class I and II loci [50,51].”
BackgroundCD28 Superagonists: What Makes the Difference in Humans?
Schraven, B. L., & Kalinke, U. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.003 · Cited by 63
Identifying and hurdling obstacles to translational research
Sabroe, I., Dockrell, D. H., Vogel, S. N., Renshaw, S. A., Whyte, M. K. B., & Dower, S. (2006) · Nature reviews. Immunology · doi:10.1038/nri1999 · Cited by 59
“Recently, differential expression of SIGLECs (sialicacid-binding immunoglobulin-like lectins), which are inhibitory receptors thought to downregulate immune-cell activation, has been noted between apes and humans 16 , and such differences in immune responses between species require careful consideration, as highlighte…”
BackgroundSystem-wide Genomic and Biochemical Comparisons of Sialic Acid Biology Among Primates and Rodents
Altheide, T. K., Hayakawa, T., Mikkelsen, T. S., Diaz, S. L., Varki, N. M., & Varki, A. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604221200 · Cited by 73
Self-citationHost immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes
Chung, S. H., Mollhoff, I. N., Mishra, A., Sin, T.-N., Ngo, T., Ciulla, T., Sieving, P., Thomasy, S. M., & Yiu, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.281 · Cited by 57
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies
Hünig, T. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)95004-x · Cited by 57
Soto, P. C., Stein, L. L., Hurtado-Ziola, N., Hedrick, S. M., & Varki, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903420 · Cited by 56
“Our previous findings looking at the difference in Siglec expression between humans and chimpanzees show that in total lymphocyte populations, the levels of Siglec expression appear to be similar (39).”
BackgroundMethodResultSelf-citationA more selective costimulatory blockade of the CD28-B7 pathway
Poirier, N., Blancho, G., & Vanhove, B. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01176.x · Cited by 54
“Finally, a more convincing explanation could be a relative loss of expression of inhibitory sialic acid-recognizing Ig-superfamily lectins (Siglec, CD33) on T and B lymphocytes during human evolution, in particular Siglec-5 [88,89].”
BackgroundToxicity as a result of immunostimulation by biologics
Gribble, E. J., Sivakumar, P. V., Ponce, R. A., & Hughes, S. D. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.209 · Cited by 52
“This relative sensitivity of humans appears to be based on the differential expression of CD33-related sialic acid-recognizing Ig-superfamily lectins that downregulate cell activation in primates, but have low expression in human T cells [181].”
BackgroundCD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?
Poirier, N., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04032.x · Cited by 52
“Moreover, expression at high level of inhibitory sialic acidrecognizing Ig-superfamily lectins (Siglec, CD33) on lymphocytes was lost during human evolution, in particular Siglec-5 (29,30).”
BackgroundDharmadhikari, G., Stolz, K., Hauke, M., Morgan, N. G., Varki, A. P., de Koning, E. J. P., Kelm, S., & Maedler, K. (2017) · Scientific Reports · doi:10.1038/srep45319 · Cited by 55
Self-citationVarki, A. P. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.011 · Cited by 46
“In this regard a striking finding is that the complement of CD33rSiglecs that are displayed on chimpanzee T and B cells are much less prominent on humanTcells, even though the genes are shared [66].”
BackgroundSelf-citationSiglec-7 engagement by GBS β-protein suppresses pyroptotic cell death of natural killer cells
Fong, J. J., Tsai, C.-M., Saha, S., Nizet, V., Varki, A., & Bui, J. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804108115 · Cited by 45
“As Siglec-5 is not prominent on human lymphocytes (29), it is not clear whether GBS β-protein can also inhibit this class of leukocytes.”
BackgroundSelf-citationStewart, N., Daly, J. M., Drummond-Guy, O., Krishnamoorthy, V., Stark, J. C., Riley, N. M., Williams, K. C., Bertozzi, C. R., & Wisnovsky, S. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105579 · Cited by 46
“S8), matching reports from prior studies (45).”
Cao, H., de Bono, B., Belov, K., Wong, E. S. W., Trowsdale, J., & Barrow, A. D. (2009) · Immunogenetics · doi:10.1007/s00251-009-0372-0 · Cited by 45
Possible Influences of Endogenous and Exogenous Ligands on the Evolution of Human Siglecs
Angata, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02885 · Cited by 46
Cell type–specific glycosylation of Orai1 modulates store-operated Ca 2+ entry
Dörr, K., Kilch, T., Kappel, S., Alansary, D., Schwär, G., Niemeyer, B. A., & Peinelt, C. (2016) · Science Signaling · doi:10.1126/scisignal.aaa9913 · Cited by 46
“Compared to great apes, Siglec protein abundance inT cells is decreased in humans (10).”
BackgroundNegative regulation of leucocyte functions by CD33-related siglecs
Avril, T., Attrill, H., Zhang, J., Raper, A., & Crocker, P. R. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341024 · Cited by 45
Animal models and conserved processes
Greek, R., & Rice, M. J. (2012) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-9-40 · Cited by 47
“Significant differences in the details of conserved processes (also illustrated by Figure 1 [156]) mean that there are”
BackgroundCostimulation Blockade in Kidney Transplantation: An Update
Malvezzi, P., Jouvé, T., & Rostaing, L. P. E. (2016) · Transplantation · doi:10.1097/tp.0000000000001344 · Cited by 47
“The specific loss of human Tcell Siglec expression thereby resulted in T cell hyperactivity.(51)”
BackgroundHuman-Specific Evolutionary Changes in the Biology of Siglecs
Schwarz, F., Fong, J. J., & Varki, A. P. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-11280-0_1 · Cited by 41
Self-citationPre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
Basner-Tschakarjan, E., Bijjiga, E., & Martino, A. T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00028 · Cited by 39
“Varki and colleagues reported the loss of siglec receptor expression in T lymphocytes during human evolution (37).”
Soluble siglec-5 is a novel salivary biomarker for primary Sjogren's syndrome
Lee, J. J., Lee, J., Baek, S.-Y., Koh, J. H., Kim, J., Kim, S., Chung, S., Choi, S. S., Cho, M., Kwok, S., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.03.008 · Cited by 39
Metadata
- Authors
- Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A.
- Affiliations
- University of California San Diego (US)
- *Glycobiology Research and Training Center and Departments of Medicine and Cellular and Molecular Medicine, and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2006-05-16
- Volume
- 103
- Issue
- 20
- Pages
- 7765-7770
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2142499414
- Cited by
- 204
- References
- 39
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 12 · 2021: 7 · 2020: 6 · 2019: 7 · 2018: 8 · 2017: 8 · 2016: 11 · 2015: 7 · 2014: 11 · 2013: 10 · 2012: 12
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health (GM32373)
- Yerkes National Primate Research Center, Emory University
- National Heart, Lung, and Blood Institute (P01HL057345)
- National Institute of General Medical Sciences (R01GM032373, R01-GM-32373)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- Siglecs, Siglec-5, T cells, chimpanzees, great apes, human evolution, T cell receptor signaling, inhibitory signaling, T cell proliferation, AIDS, chronic active hepatitis, ITIM
- MeSH terms
- Animals, B-Lymphocytes, Calcium, Pan troglodytes, Biological Evolution, Humans, Lymphocyte Activation, Receptors, Antigen, T-Cell, Sialic Acids, T-Lymphocytes, Antigens, Differentiation, Myelomonocytic, Down-Regulation, Antigens, CD, Lectins, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.